B. Craig Owens
Known title: DirectorCIK: 0001446362
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
Transaction History
| CCK | ▲ Buy | Grant | 351 | $41K | 7/29/2026 | View on chart |
| ATR | ▲ Buy | Grant | 151 | $0 | 7/16/2026 | View on chart |
| CCK | ▲ Buy | Grant | 417 | $41K | 5/6/2026 | View on chart |
| ATR | ▲ Buy | Grant | 1,326 | $0 | 5/6/2026 | View on chart |
| CCK | ▲ Buy | Grant | 371 | $41K | 2/13/2026 | View on chart |
| CCK | ▲ Buy | Grant | 406 | $40K | 10/29/2025 | View on chart |
| CCK | ▲ Buy | Grant | 389 | $40K | 7/30/2025 | View on chart |
| CCK | ▲ Buy | Grant | 414 | $40K | 5/7/2025 | View on chart |
| ATR | ▲ Buy | Grant | 1,069 | $0 | 5/7/2025 | View on chart |
| CCK | ▲ Buy | Grant | 454 | $40K | 2/14/2025 | View on chart |
| CCK | ▲ Buy | Grant | 420 | $40K | 10/28/2024 | View on chart |
| CCK | ▲ Buy | Grant | 466 | $40K | 7/31/2024 | View on chart |
| CCK | ▲ Buy | Grant | 482 | $40K | 5/8/2024 | View on chart |
| ATR | ▲ Buy | Grant | 1,113 | $0 | 5/1/2024 | View on chart |
| CCK | ▲ Buy | Grant | 536 | $40K | 2/14/2024 | View on chart |
| CCK | ▲ Buy | Grant | 499 | $40K | 11/1/2023 | View on chart |
| CCK | ▲ Buy | Grant | 428 | $40K | 8/2/2023 | View on chart |
| CCK | ▲ Buy | Grant | 475 | $40K | 5/3/2023 | View on chart |
| ATR | ▲ Buy | Grant | 1,266 | $0 | 5/3/2023 | View on chart |
| CCK | ▲ Buy | Grant | 465 | $40K | 2/16/2023 | View on chart |
| CCK | ▲ Buy | Grant | 583 | $40K | 11/2/2022 | View on chart |
| CCK | ▲ Buy | Grant | 413 | $40K | 7/29/2022 | View on chart |
| CCK | ▲ Buy | Grant | 363 | $40K | 5/4/2022 | View on chart |
| ATR | ▲ Buy | Grant | 1,302 | $0 | 5/4/2022 | View on chart |
| CCK | ▲ Buy | Grant | 336 | $40K | 2/17/2022 | View on chart |
| CCK | ▲ Buy | Grant | 348 | $36K | 11/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Crown Holdings Price Target to $116
UBS has lowered its price target for Crown Holdings to $116 while maintaining a Neutral rating. This new target is below the current support level of $118.66, suggesting potential downside pressure. The move stands out as the new target is significantly lower than the average analyst estimate of $136.57.
UBS Cuts Crown Holdings Price Target to $116. UBS has lowered its price target for Crown Holdings to $116 while maintaining a Neutral rating. This new target is below the current support level of $118.66, suggesting potential downside pressure. The move stands out as the new target is significantly lower than the average analyst estimate of $136.57.